Ipamorelin is a GHRP (growth hormone releasing peptide) that mimics ghrelin to produce a short, selective GH pulse from the pituitary gland. It is used in research for recovery, sleep quality, and general GH support. It is not FDA-approved.

Tesamorelin is a GHRH analog that is FDA-approved to reduce excess visceral fat (deep belly fat around the organs) in adults with HIV-associated lipodystrophy. It is sold as Egrifta. Off-label use for general fat loss is not FDA-approved.

Ipamorelin vs Tesamorelin: Which Cuts More Belly Fat?

Q: Does tesamorelin reduce belly fat?

Yes, in its FDA-approved indication. Clinical trials show tesamorelin significantly reduces visceral adipose tissue (belly fat around the organs) in people with HIV-associated lipodystrophy [verify: source]. Its effect on visceral fat in the general population is less well studied.

Q: Can you stack ipamorelin and tesamorelin?

Some researchers do combine them. Ipamorelin acts on ghrelin receptors and tesamorelin acts on GHRH receptors, so they use different entry points to trigger GH release. This is similar to the ipamorelin and CJC-1295 stack. However, this is off-label territory with limited human data [verify: source].

Built by medical professionals, gym rats, and experienced biohackers

Tesamorelin is the one specifically designed and approved for belly fat reduction. Ipamorelin supports GH more broadly and is not approved for fat loss specifically.

Ipamorelin or Tesamorelin: Which One Targets Belly Fat?

Tesamorelin (Egrifta) is an FDA-approved GHRH analog. Clinical trials show it reduces visceral fat (the deep belly fat around your organs) in people with HIV-associated lipodystrophy (source). Ipamorelin is a GHRP used in research for GH support, recovery, and sleep quality. It is not targeted at fat loss in the same way. If cutting visceral fat is the specific goal, tesamorelin is the more targeted compound.

What Is Ipamorelin?

Ipamorelin is a GHRP (growth hormone releasing peptide). It mimics ghrelin, the hunger hormone your stomach produces, which triggers a short burst of GH from the pituitary gland.

Its main appeal is its clean profile. It does not significantly raise cortisol (a stress hormone) or prolactin (source). High levels of either can cause problems. This makes it popular for recovery, sleep quality, and broader GH support.

It is injected under the skin (subcutaneous) and peaks within 30 to 60 minutes. It is typically used 1 to 3 times daily . It is not FDA-approved.

What Is Tesamorelin?

Tesamorelin is a GHRH analog. GHRH (growth hormone releasing hormone) is the signal your brain uses to tell the pituitary gland to produce GH. Tesamorelin is a synthetic copy of that signal.

What makes tesamorelin stand out is its FDA approval. It is the only peptide with an FDA-approved indication specifically linked to reducing visceral fat (fat around the organs). That indication covers adults with HIV-associated lipodystrophy. This is a condition where fat builds up in the belly and decreases in the limbs .

Tesamorelin is sold as Egrifta and is injected daily at 2 mg (source).

Off-label use by people without HIV for general body composition is not approved and has limited study data.

How Do They Differ?

Feature	Ipamorelin	Tesamorelin
Type	GHRP (ghrelin receptor agonist)	GHRH analog
Mechanism	Triggers GH pulse via ghrelin receptors	Mimics GHRH to drive sustained GH release
FDA approval	No	Yes (for HIV-related lipodystrophy)
Primary studied use	Recovery, sleep, GH support (research)	Visceral fat reduction in HIV-associated lipodystrophy
Typical dose	100 to 300 mcg per injection	2 mg per day
Injection frequency	1 to 3 times daily	Once daily
Onset for fat effect	Not well established for fat loss	Significant visceral fat reduction seen over 26 weeks
Evidence level	Limited human trial data	Completed human trials for FDA indication

Mechanism difference. Ipamorelin acts on ghrelin receptors to pulse GH. Tesamorelin acts on GHRH receptors to drive a sustained increase in GH. Both pathways raise GH. Tesamorelin's sustained GH elevation may be more effective at shifting the body toward burning stored visceral fat .

Targeted vs general. This is the most important practical distinction. Tesamorelin's clinical trials were designed to measure visceral fat specifically. Ipamorelin is studied in the context of general GH support, recovery, and wellbeing. It has not been studied head to head with tesamorelin for fat loss.

Approval and access. Tesamorelin requires a prescription and has a defined clinical indication. Ipamorelin is a research compound not available by standard prescription.

Evidence quality. Tesamorelin has completed Phase 3 trials showing significant visceral fat reduction in its approved population . Ipamorelin has limited human trial data. Neither should be assumed to produce the same results in people outside the studied populations.

Can You Stack Ipamorelin and Tesamorelin?

Some researchers and biohackers do combine them. The logic is similar to the ipamorelin and CJC-1295 stack. Ipamorelin uses ghrelin receptors and tesamorelin uses GHRH receptors. Because they are different receptor types, they do not block each other and may produce a synergistic GH response .

That said, this combination is off-label even for tesamorelin. There is limited human data on the combination specifically.

If you are running any multi-peptide protocol, a clear log of what you took and when is worth keeping. DoseVault is built for exactly that kind of structured tracking across a long protocol.

Frequently Asked Questions

What is ipamorelin?
Ipamorelin is a GHRP that mimics ghrelin for a clean, selective GH pulse. It is used in research for GH support, recovery, and sleep quality.

What is tesamorelin?
Tesamorelin is an FDA-approved GHRH analog prescribed to reduce visceral belly fat in adults with HIV-associated lipodystrophy. It is sold as Egrifta.

Does tesamorelin reduce belly fat?
Yes, in its studied population. Clinical trials show significant visceral fat reduction in adults with HIV-associated lipodystrophy (source). Its effect on general populations is less studied.

Can you stack ipamorelin and tesamorelin?
Some researchers do. They work through different receptors (ghrelin vs GHRH), which means they can complement each other. But this is off-label territory with limited human data (source).

Which Do People Pick, and When?

This is general guidance, not personalized medical advice. Talk to a licensed clinician before starting any peptide protocol.

Choose tesamorelin if:
- Reducing visceral fat is your specific goal
- You have access to a prescribing clinician who supports its use
- You want a compound with human clinical trial data supporting its fat-loss effect

Choose ipamorelin if:
- Your goal is broader: GH support, recovery, better sleep, or general wellness
- You want a clean GH pulse with minimal cortisol or prolactin impact
- You are exploring research compounds and not seeking a fat-loss-specific drug

Consider both if:
- Your clinician supports a combined GHRH and GHRP protocol
- You want both the targeted visceral fat effect and the clean pulsed GH support

This page is educational only. It is not medical advice and does not replace consultation with a licensed healthcare provider. Tesamorelin is a prescription drug. Ipamorelin is not FDA-approved for general use. Do not use these compounds to diagnose, treat, cure, or prevent any condition.

Built by medical professionals, gym rats, and experienced biohackers

Tracking a peptide or GH protocol over multiple weeks? DoseVault helps you log doses, monitor how you feel, and build a clear picture of your full protocol history.